Progyny price target raised to $50 from $45 at KeyBanc

KeyBanc analyst Scott Schoenhaus raised the firm’s price target on Progyny to $50 from $45 and keeps an Overweight rating on the shares. Progyny reported another solid top- and bottom-line beat with record utilization that hit 0.50% for females only and 0.57% for all members, the analyst tells investors in a research note.